Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension (PAH)
Comparison of Sequential to Initial Combination Therapy in PAH
This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH).
- Trial name
- ORIENTATION (NCT06968962)
- Testing
- Tadalafil, Ambrisentan, Ambrisentan mimic
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pulmonary Arterial Hypertension
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone
- Trial name
- NCT04062565
- Testing
- Treprostinil Injectable Product, Riociguat Pill
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arizona
Pulmonary Arterial Hypertension
Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans
The goal of our study is to correlate data from non-invasive tests such as perfusion lung scans with hemodynamic measurements from right heart catherizations.
- Trial name
- NCT00621075
- Testing
- Pulmonary Arterial Hypertension - Lung Perfusion Scans
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Northwell Health
Coronary Artery Disease, Hypertension
China Elderly Comorbidity Medical Database
The objective of this observational cohort study is to provide comprehensive evaluation and early warning for elderly patients with chronic diseases.
- Conditions
- Coronary Artery Disease, Hypertension, Diabetes Mellitus, Osteoporosis
- Trial name
- CECMed (NCT06316544)
- Where
- China
- Volunteers
- 4,100 people
- Sponsor
- Beijing Friendship Hospital
Pulmonary Arterial Hypertension
Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
Pulmonary hypertension is characterized by an increase in the pressures in the blood supply to the lungs greater than a mean pressure of 25mmHg and a concomitant increase in overall pulmonary vascular resistance (PVR).
- Trial name
- NCT02734953
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Angina Pectoris, Acute Coronary Syndrome
Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19
Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure…
- Conditions
- Angina Pectoris, Acute Coronary Syndrome, Coronary Syndrome, Coronary Artery Disease
- Trial name
- eCardioCovid19 (NCT04325867)
- Testing
- Tele-medicine platform
- Where
- 2 sites in Romania
- Volunteers
- 200 people
- Sponsor
- Professor Adrian Covic
Erectile Dysfunction, Pulmonary Arterial Hypertension
Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function
The study aims to investigate and compare the effect of TPN171H on subjects with mild and moderate hepatic impairment compared to healthy subjects.
- Trial name
- NCT05185011
- Testing
- TPN171H
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Pulmonary Arterial Hypertension
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study.
- Trial name
- NCT01560637
- Testing
- UT-15C (treprostinil diolamine)
- Where
- 153 sites in United States, Argentina and 21 more
- Volunteers
- 471 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary Arterial, Out-Of-Hospital Cardiac Arrest
REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study)
Background: For patients with out-of-hospital cardiac arrest (OHCA) at the intensive care unit (ICU), oxygen therapy plays an important role in post resuscitation care.
- Conditions
- Hypertension, Pulmonary Arterial, Out-Of-Hospital Cardiac Arrest, Intensive Care Unit, Oxygen Therapy
- Trial name
- RELIEPH (NCT05029167)
- Testing
- Restrictive PaO2, Low normal MAP, Liberal PaO2
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- University of Southern Denmark
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are severe clinical conditions that, despite advances in therapeutics over the past 20 years, lead to serious morbidity and…
- Trial name
- NCT05618093
- Testing
- Non-invasive hemodynamic measurements
- Where
- United States
- Sponsor
- University of California, Los Angeles
Hypertension
The Assessment of Right Ventricular Contractility in Response to Sildenafil
The primary objective of this study is to examine the effects of Sildenafil, administered during cardiac catheterization, on right ventricular contractility in children with pulmonary arterial hypertension.
- Trial name
- NCT00742014
- Testing
- Sildenafil
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- The Hospital for Sick Children
Pulmonary Arterial Hypertension
The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension
Exploring the safety, tolerability, and pharmacokinetic (PK) characteristics of oral TPN171H tablets in patients with Pulmonary Arterial Hypertension under continuous multiple administration conditions, providing a basis for…
- Trial name
- NCT05948644
- Testing
- TPN171H
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Vigonvita Life Sciences
Pulmonary Arterial Hypertension
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.
- Trial name
- TRUST-2 (NCT03055221)
- Testing
- Intravenous Treprostinil
- Volunteers
- 20 people
- Sponsor
- United Therapeutics
Refractory Lupus Nephritis, Systemic Sclerosis
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
- Trial name
- NCT06947460
- Testing
- CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Pulmonary Arterial Hypertension
Assessmet of Patients With PAH Right Ventricular Volume
The primary endpoint of this study is the percent difference between the VentriPoint Medical System (VMS) and cMRI for estimating the end diastolic and end systolic right ventricular volumes (RVEDV and RVESV) in subjects with…
- Trial name
- NCT01557582
- Testing
- Ventripoint Medical System
- Where
- 7 sites in United States, Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VentriPoint Diagnostics Ltd.
Pulmonary Arterial Hypertension
Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare and severe disease characterized by elevation of pulmonary artery pressure (PAP) and increased pulmonary vascular resistance (PVR) due to the narrowing of small pulmonary arteries.
- Trial name
- PAHexercise (NCT06804122)
- Testing
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Tampere Heart Hospital
Pulmonary Arterial Hypertension
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
- Trial name
- NCT00423202
- Testing
- ambrisentan
- Volunteers
- 186 people
- Sponsor
- Gilead Sciences
Asthma, Coronary Artery Disease
Care Transitions for Complex Patient - Cycle 1 and Cycle 2
The purpose of this study is to improve patient care and safety while decreasing ED visit rates by sending specific information about care transitions related to hospital admission and discharge and emergency department and…
- Conditions
- Asthma, Coronary Artery Disease, Diabetes, Hypertension
- Trial name
- NCT01039324
- Testing
- Reports, Reports and Notices, Usual care
- Where
- United States
- Volunteers
- 8,422 people
- Sponsor
- Duke University
Pulmonary Arterial Hypertension
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
- Trial name
- IMPRES (NCT00902174)
- Testing
- imatinib mesylate
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
PAH
Pulmonary Hypertension and Imatinib
The purpose of the study is to determine whether circulating molecular and cellular biomarkers are predictive of imatinib effect on pulmonary artery hypertension.
- Trial name
- NCT01092897
- Where
- 8 sites in United States
- Volunteers
- 130 people
- Sponsor
- The Cleveland Clinic